Portal de investigación
ESTUDIO DE OPTIMIZACIÓN DE DOSIS DE IDELALISIB EN EL LINFOMA FOLICULAR Y LINFOMA LINFOCÍTICO DE CÉLULAS PEQUEÑAS.
Datos básicos
- Código:
- GS-US-313-1580
- Protocolo:
- GS-US-313-1580
- EUDRACT:
- 2015-000366-66
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2016
- Año de finalización:
- 2020
Objetivos del proyecto
Observaciones: Estado Comité: ACTIVO
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
18 FDG PET/CT PREDICTS DECLINE IN FUNCTIONAL RESPIRATORY TESTS IN SYSTEMIC SCLEROSIS PATIENTS BUT NOT IN RHEUMATOID ARTHRITIS PATIENTS
Meeting Abstract. 10.1136/annrheumdis-2018-eular.6844. 2018
18 F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with polymyalgia rheumatica: Screening for vasculitis.
Arévalo Ruales K; (...); Román Ivorra JA
Article. 10.1016/j.reuma.2018.02.009. 2020
18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.
Cordoba, Raul; (...); Martin Garcia-Sancho, Alejandro
Article. 10.1080/17474086.2024.2313457. 2024
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.
Provencio-Pulla, Mariano; (...); Rueda, Antonio
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.7550. 2018
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients.
Lozano ML; (...); Vicente V
Article. 10.1016/j.bcmd.2020.102505. 2021
A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).
Martínez-Banaclocha N; (...); Gumà J
Article. 10.3390/cancers16051034. 2024
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)
Vallejo C; (...); Codesido ML
Article. 10.1007/s00277-023-05602-x. 2024
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; (...); Martínez-Olmos J
Article. 10.1007/s41669-020-00201-2. 2020
A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.
Casado, MA; (...); Grp MULTIDEX-EMD
Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018
A new definition and refocus of pharmaceutical care: the Barbate Document
Morillo-Verdugo R; (...); Poveda-Andrés JL
Article. 10.7399/fh.11389. 2020
A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Lopez-Guillermo, Armando; (...); Tomas, Jose Francisco
Article. 10.1080/10428194.2021.1971216. 2021
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, Cristina; (...); Martinez-Lopez, Joaquin
Article. 10.1038/s41408-022-00652-2. 2022
A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Article. 10.1038/tpj.2015.80. 2016
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review
Review. 10.1177/20406207211038181. 2021
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
Stadtmauer, Edward A.; (...); ZOE-SCT Study Grp Collaborators
Article. 10.1080/21645515.2021.1953346. 2021
Aflibercept in exudative age related macular degeneration refractory to ranibizumab.
Ruiz Ramos J; (...); Gallego-Pinazo R
Article. 10.1016/j.oftal.2015.07.018. 2015
An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib
Diaz-Beveridge, R; (...); Aparicio, J
Article. 10.1007/s12094-017-1720-4. 2018
Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia, X; (...); Tort, M
Article. 10.7399/fh.11147. 2019
Analysis of autophagy gene polymorphisms in Spanish patients with head and neck squamous cell carcinoma
Fernandez-Mateos, J; (...); Gonzalez-Sarmiento, R
Article. 10.1038/s41598-017-07270-0. 2017
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
ANALYSIS OF PROGRESSION-FREE SURVIVAL OF AND GLOBAL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA OLDER THAN 65 YEARS CANDIDATES FOR AUTOLOGOUS PERIPHERAL BLOOD TRANSPLANTATION NON-CANDIDATES
Cejalvo, MJ; (...); De la Rubia, J
Meeting Abstract. 2017
ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION.
Cejalvo, MJ; (...); De la Rubia J
Meeting Abstract. 2018
Antimicrobial stewardship programme implementation in a medical ward
Ruiz, J; (...); Poveda, JL
Article. 2018
Antimicrobial stewardship programme in critical care medicine: A prospective interventional study
Ruiz, J; (...); Catellanos, A
Article. 10.1016/j.medin.2017.07.002. 2018
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Assessment of the dicentric chromosome assay as a biodosimetry tool for more personalized medicine in a case of a high risk neuroblastoma I-131-mIBG treatment
Chimeno, JM; (...); Montoro, A
Article. 10.1080/09553002.2019.1549755. 2018
Assessment of the quality of sample labelling for clinical research.
Pérez-Huertas P; (...); Poveda-Andrés JL
Article. 10.7399/fh.2016.40.2.9753. 2016
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-017-2933-6. 2017
Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
García-Sancho AM; (...); Caballero D
Article. 10.3324/haematol.2021.279426. 2022
Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure
Jiménez-Ubieto A; (...); Lahuerta JJ
Article. 10.1016/j.bbmt.2017.05.021. 2017
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment
Jimenez-Ubieto, A; (...); GELTAMO Grp Espanol Linfomas Tr
Article. 10.1002/hon.2553. 2018
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy.
Jiménez-Ubieto A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Stu
Article. 10.1016/j.hemonc.2019.06.001. 2019
Autologous Stem Cell Transplantation may potentially abrogate the negative prognostic effect of early relapse after chemo or inmunochemotherapy in Follicular Lymphoma
Ubieto, AJ; (...); Lahuerta, JJ
Meeting Abstract. 2018
AUTONOMOUS TRANSPLANTATION CAN MITIGATE THE ADVERSE PROGNOSIS OF THE EARLY RELAPSE AFTER CHEMO OR IMMUNOCHEMOTHERAPY INDUCTION IN FOLLICULAR LYMPHOMA
Ubieto, AJ; (...); Lahuerta, J. J.
Meeting Abstract. 2017
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).
Pascual-Izquierdo C; (...); Mingot-Castellano ME
Article. 10.1002/ajh.27498. 2024
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients.
SAnchez, JosE GarcIa; (...); Lahoz, Agustin
Meeting Abstract. 2020
Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
Redondo, AM; (...); GEL-TAMO
Article. 10.1111/bjh.15713. 2019
Bendamustine plus rituximab in untreated chronic lymphocytic leukemia patients. The MDA-CLL-2015-02 study
De La Fuente, A; (...); Baltasar, P
Meeting Abstract. 2017
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
BK Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation in the Pediatric Population
Perez-Huertas, P; (...); Poveda-Andres, JL
Article. 10.1177/1043454216631952. 2017
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma.
Rosiñol L; (...); Bladé J
Article. 10.1182/blood.2019000241. 2019
Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience
Garcia-Robles, AA; (...); Fernandez-Navarro, JM
Meeting Abstract. 2017
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L; (...); de la Cruz-Merino L
Article. 10.3389/fimmu.2024.1293931. 2024
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2020.12.019. 2021
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
Jimenez-Cortegana, C; (...); de la Cruz-Merino, L
Article. 10.1136/jitc-2020-002323. 2021
Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
Rodriguez-Pinilla SM; (...); Cordoba, Raul
Article. 10.1111/bjh.16741. 2021
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre
Arnao, M; (...); Sanz, G
Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019
Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model
Nogueras, A; (...); Calleja, MA
Letter. 10.1136/ejhpharm-2019-001905. 2019
Collaborative model of home delivery program in haemophilia through an association of patients
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation
Article. 10.1111/ejh.13270. 2019
COMPREHENSIVE LONG-TERM FOLLOW-UP OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REPORT FROM A SINGLE CENTRE
Sempere, A.; (...); Jarque, I.
Meeting Abstract. 2016
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years
Provencio, M; (...); Rueda, A
Letter. 10.1080/10428194.2018.1509322. 2019
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.1080/13696998.2017.1311903. 2017
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; (...); Torres C
Article. 10.1080/14737167.2019.1635014. 2020
COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN
Trillo, JL; (...); Torres, C
Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia
Casado, LF; (...); Castro, A
Article. 10.1111/ejh.13007. 2018
COST-UTILITY OF IDELALISIB IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Casado, LF; (...); Castro-Gomez, A
Meeting Abstract. 10.1016/j.jval.2017.08.898. 2017
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study
Mesia, R; (...); Spanish Head Neck Canc Cooperative
Article. 10.1016/j.ijrobp.2016.11.016. 2017
CRITICAL REVIEW OF THE DOUBLE NEGATIVITY IN THE SERUM AND URINE IMMUNOFIXATION (IF) TO ESTABLISH THE CATEGORY OF COMPLETE REMISSION IN MULTIPLE MYELOMA (MM)
Anglada, LL; (...); Lahuerta, J. J.
Meeting Abstract. 2017
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.
Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina
Article. 10.1093/mmy/myac038. 2022
Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.
Calleja-Panero, Jose Luis; (...); Gonzalez Calvo, Jose
Article. 10.1016/j.gastrohep.2023.05.010. 2023
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (vol 11, 16867, 2021)
Lozano, Maria L.; (...); Vicente, Vicente
Article. 10.1038/s41598-021-95732-x. 2021
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
Lozano ML; (...); Vicente V
Article. 10.1038/s41598-019-53209-y. 2019
Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project
Blade, J; (...); Lizan, L
Article. 10.1136/bmjopen-2017-018850. 2018
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
DETERMINATION OF THE CHALLENGES AND OPPORTUNITIES ASSOCIATED WITH PLATELET TRANSFUSION IN THE MANAGEMENT OF PATIENTS WITH SEVERE THROMBOCYTOPENIA ASSOCIATED WITH CHRONIC LIVER DISEASE
Jarque, Ramos, I; (...); Shepherd, Moreno J.
Meeting Abstract. 2020
DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN
Andrade, R.; (...); Shepherd, J.
Meeting Abstract. 2019
Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Alvarez-Roman, MT; (...); Badia, X
Article. 10.1177/2284240319880534. 2019
DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Alvarez, E.; (...); Badia, F. J.
Meeting Abstract. 2019
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.
Simarro J; (...); Palanca S
Article. 10.3390/cancers11081196. 2019
Diffusion tensor imaging as a prognostic biomarker for motor recovery and rehabilitation after stroke
Puig, J; (...); Pedraza, S
Review. 10.1007/s00234-017-1816-0. 2017
Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-125557. 2019
Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases
Megias-Vericat, JE; (...); Poveda, JL
Review. 10.1007/s10072-017-2833-9. 2017
Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations
Salvador-Coloma, C; (...); Juan, O
Article. 10.21037/jtd.2018.02.30. 2018
Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant
Solano C; (...); Bow EJ
Article. 10.1111/myc.12552. 2017
Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan
Ribera, E; (...); Hernandez-Novoa, B
Article. 10.1016/j.eimc.2016.11.015. 2018
Editorial: Infectious diseases and hematology: diagnosis and management
Gonzalez-Lopez, Tomas Jose; (...); Di Micco, Pierpaolo
Editorial Material. 10.3389/fmed.2024.1385874. 2024
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
EFFECT OF PREGNANCY IN THE CLINICAL COURSE OF PREGNANT WOMEN WITH PTI AND THEIR OFFSPRING. RESULTS OF A SERIES OF SPANISH CASES WITH 263 PREGNANCIES IN PRIMARY PTI
Lopez, TJG; (...); Hermida, G.
Meeting Abstract. 2017
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial
Bastidas, A; (...); ZOE-HSCT Study Grp Collaborators
Article. 10.1001/jama.2019.9053. 2019
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Efficacy RENO Study Results of Oral Vinorelbine or Etoposide with Cisplatin Et Chemo-Radiation in Stage III NSCLC. SLCG 10/02
Isla, D; (...); Provencio, M
Meeting Abstract. 10.1016/j.jtho.2016.11.421. 2017
eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Megias-Vericat, JE
Meeting Abstract. 2018
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; (...); Risitano AM
Article. 10.1056/NEJMoa2109965. 2022
ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL
Risitano, A. M.; (...); de latour, R. Peffault
Meeting Abstract. 2021
ELTROMBOPAG ADDED TO STANDARD IST IS SUPERIOR TO IST ALONE AS FRONT-LINE TREATMENT FOR SEVERE APLASTIC ANEMIA: FINAL 2-YEAR ANALYSIS OF EBMT-SAAWP RACE STUDY
Risitano, Antonio Maria; (...); de Latour, Regis Peffault
Meeting Abstract. 2024
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
González-López TJ; (...); González-Porras JR
Article. 10.1111/ejh.12725. 2016
Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location
Seijas-Tamayo, R; (...); Cruz-Hernandez, JJ
Article. 10.1007/s12094-016-1493-1. 2016
Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population
Fernandez-Mateos, J; (...); Spanish Head Neck Canc Cooperative
Article. 10.1016/j.oraloncology.2016.10.006. 2016
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rosell, R; (...); BELIEF collaborative group
Article. 10.1016/S2213-2600(17)30129-7. 2017
EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
Badia, F. J.; (...); Shepherd, J.
Meeting Abstract. 2019
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies.
Gudiol C; (...); de la Cámara R
Article. 10.1016/j.eimc.2019.01.013. 2020
Experience of Home Delivery Program in Haemophilia Through an Association of Patients
Megias Vericat, J. E.; (...); Bonanad Boix, S.
Meeting Abstract. 2017
Exploratory analysis for the implementation of antineoplastic logarithmic dose banding
Albert-Mari, A; (...); Poveda-Andres, JL
Article. 10.1007/s11096-018-0714-9. 2018
EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
F, de Andres-Nogales; (...); Martinez, M.
Meeting Abstract. 2019
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish; (...); Prince, H. Miles
Meeting Abstract. 10.1182/blood-2023-179818. 2023
Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: Study PANTERA
Trufero, JM; (...); Cruz-Hernandez, J
Meeting Abstract. 2019
Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC - SLCG 10/02
Pulla, MP; (...); Casado, MDI
Meeting Abstract. 2018
Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin and chemoradiation in stage III NSCLC. SLCG 10/02.
Provencio-Pulla, Mariano; (...); Isla, Dolores
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e20521. 2018
Follicular lymphoma: clinical and mollecular characteristics of histologic transformation
Garcia, MM; (...); Pulla, MP
Meeting Abstract. 2017
Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
Gonzalez-Lopez, Tomas Jose; (...); Garcia-Donas Gabaldon, Gloria
Article. 10.1182/blood.2024024250. 2024
Frequency, characteristics and outcomes of Lymphoproliferative Disorders After Allogeneic Stem Cell Transplant: results of a multicenter study from the Grupo Espanol de Trasplante Hematopoyetico (GETH)
Garcia Cadenas, Irene; (...); Solano, Carlos
Meeting Abstract. 2018
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)
Garcia-Cadenas, I; (...); Spanish Grp Blood & Marrow Tran
Article. 10.1111/ejh.13226. 2019
GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (> 65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES
Bonanad, S; (...); de la Rubia, J
Meeting Abstract. 2017
Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population
Fernandez-Mateos, J; (...); Cruz-Hernandez, JJ
Article. 10.3390/cancers11040493. 2019
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
GUIDELINES OF PRESCRIPTION IN FIRST LINE OF PATIENTS WITH MULTIPLE MYELOMA NOT CANDIDATES TO TRANSPLANTATION STRATIFIED BY AGE IN REAL LIFE IN SPAIN BETWEEN 2012 AND 2016
Cejalvo, M. J.; (...); Sarra, J.
Meeting Abstract. 2019
Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12568. 2017
Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study
Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units
Article. 10.7399/fh.10935. 2018
Hazardous drugs: new challenges, new opportunities.
Valero García S; (...); Poveda Andrés JL
Article. 10.7399/fh.2016.40.2.10462. 2016
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
Iskierka-Jazdzewska, Elzbieta; (...); Ivanescu, Cristina
Meeting Abstract. 10.1182/blood-2023-180743. 2023
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance
Garcia-Marco, JA; (...); GELLC Study Grp
Article. 10.3324/haematol.2018.204891. 2019
High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke
Puig, J; (...); Castellanos, M
Article. 10.1371/journal.pone.0188238. 2017
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.
Vallejo, Carlos; (...); Peman, Javier
Article. 10.3390/jof9060628. 2023
IMMUNE THROMBOCYTOPENIA AND PREGNANCY: A SPANISH CASE SERIES OF 270 PREGNANCIES IN PRIMARY ITP.
Gonzalez-Lopez, TJ; (...); Porras, JRG
Meeting Abstract. 2017
Immune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy
Melian Sosa, M.; (...); Lorente, D.
Meeting Abstract. 2018
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Lakhwani S; (...); Hernández MT
Article. 10.1007/s00277-024-06031-0. 2024
Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-166826. 2022
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2016.1231405. 2017
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis
Edo Solsona MD; (...); Poveda Andrés JL
Article. 10.2147/PPA.S127508. 2017
IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS
Edo-Solsona, M.; (...); Poveda-Andres, J.
Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016
Impact of an antimicrobial stewardship program on critical haematological patients.
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.7399/fh.2017.41.4.10709. 2017
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.
Simarro, Javier; (...); Palanca, Sarai
Article. 10.3390/cancers15061705. 2023
Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1038/tpj.2017.19. 2018
Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1097/FPC.0000000000000286. 2017
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Badia X; (...); Hernández C
Article. 10.1186/s13023-020-01507-4. 2020
Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry
Provencio, M; (...); GOTEL Spanish Lymphoma Oncology Gr
Article. 10.1371/journal.pone.0177204. 2017
Impact of voriconazole plasma concentrations on treatment response in critically ill patients
Ruiz, J; (...); Ramirez, P
Article. 10.1111/jcpt.12817. 2019
Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases
Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL
Article. 10.7399/fh.11262. 2020
Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.1159/000478969. 2018
INCIDENCE AND CHARACTERISTICS OF POST-TRANSPLANT ALLOGENIC LYMPHOPROLIFERATIVE SYNDROMES. EXPERIENCE OF SPANISH GROUP OF HEMATOPOIETIC TRANSPLANT (GETH)
San Segundo, LY; (...); Solano, C.
Meeting Abstract. 2017
Incidence and Management of Aplastic Anemia in Spain (IMAS). An Ambispective Study of Biodonostia / Pethema
Vallejo, C; (...); Jarque, I
Meeting Abstract. 2020
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; (...); Sanz GF
Article. 10.1007/s00277-019-03744-5. 2019
Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis
Montesinos P; (...); Sanz MA
Article. 10.1038/bmt.2015.181. 2015
Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Vericat, JEM; (...); Bonanad, S
Meeting Abstract. 2018
Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables
Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago
Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016
Infections of the Central Nervous System after Untelated Donor Umbilical Cord Blood Transplantation or Human teukocyte Antigen-Matched Sibling Transplantation
Balaguer Rosello A; (...); Sanz, J
Article. 10.1016/j.bbmt.2016.10.005. 2017
Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-122237. 2019
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2017.1323267. 2017
Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.
Ruiz J; (...); Poveda JL
Article. 10.23736/S0026-4946.18.04978-2. 2018
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Interdisciplinary recommendations document to improve adherence in patients with chronic inflammatory diseases: Adhing recommendations.
Bermejo San José F; (...); Sanromán-Álvarez L
Article. 10.7399/fh.2016.40.5.10180. 2016
Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12842. 2019
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
Invasive yeast infections in neutropenic patients
Camps, IR, Jarque, I
Review. 10.1016/j.riam.2015.11.001. 2016
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP
Article. 10.1136/ejhpharm-2020-002322. 2020
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
Rosinol, Laura; (...); Blade Creixenti, Joan
Meeting Abstract. 10.1182/blood-2021-146798. 2021
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosinol, Laura; (...); Blade, Joan
Article. 10.1182/blood.2022019531. 2023
LENALIDOMIDE IN COMBINATION WITH R-ESHAP IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL) REFRACTORY OR IN RELAPSE: STUDY PHASE 2 OF THE GELTAMO SPANISH GROUP
Baile, M.; (...); Martin, A. A.
Meeting Abstract. 2017
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Martin Garcia-Sancho, A.; (...); Caballero, D.
Article. 10.1111/bjh.18989. 2023
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis.
Palaz N-Carri N, Natalia; (...); de la Cruz-Merino, Luis
Article. 10.1158/1078-0432.CCR-22-0588. 2022
Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.
Merino, LD; (...); Dominguez, AR
Meeting Abstract. 2020
Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers
Jose Gonzalez-Lopez, Tomas; (...); Sanz, Miguel A.
Meeting Abstract. 10.1182/blood-2019-129274. 2019
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
González-Barca E; (...); de Sevilla AF
Article. 10.1007/s00277-020-04056-9. 2020
Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
De Castro, J; (...); Isla, D
Article. 10.1007/s12094-016-1527-8. 2017
Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
Melian, M; (...); Juan, O
Article. 10.1111/1759-7714.12873. 2018
Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group.
Mingot-Castellano ME; (...); González Porras JR
Article. 10.1155/2019/4621416. 2019
Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts
Calleja-Panero, JL; (...); Gil, A
Article. 10.17235/reed.2020.6895/2020. 2020
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
Metyrapone as treatment in the neonatal McCune-Albright syndrome
de Mingo, Carmen; (...); Garcia-Robles, Ana
Article. 10.1515/jpem-2020-0036. 2020
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
Valero-García S; (...); Delgado-Sánchez O
Article. 10.7399/fh.11655. 2021
Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.
Fernandez-Megia, MJ; (...); Poveda Andrés JL
Article. 10.7399/fh.10793. 2018
Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)
Franco, F; (...); Provencio, M
Article. 10.3390/curroncol28020118. 2021
Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2)
Rueda, A; (...); Mesia, R
Review. 10.1016/j.oraloncology.2017.04.005. 2017
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
Mutational profile of primary breast diffuse large B-cell lymphoma
Franco, F; (...); Sanchez-Beato, M
Article. 10.18632/oncotarget.21986. 2017
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Non-traumatic spontaneous abdominal haemorrhage
Ballesta, M.; (...); Lerga, P. Estelles
Article. 10.1016/j.rx.2022.11.003. 2023
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog; (...); Walewski, Jan
Meeting Abstract. 10.1182/blood-2022-158406. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Cabrero M; (...); Caballero D
Article. 10.1038/s41409-023-02171-5. 2024
Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial
Cabrero, M; (...); Caballero, D
Meeting Abstract. 2020
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Poveda, JL
Meeting Abstract. 2018
Opioid-Induced Constipation in Oncological Patients: New Strategies of Management.
Mesía R; (...); Pujol E
Article. 10.1007/s11864-019-0686-6. 2019
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
Isla D; (...); Provencio M
Article. 10.1016/j.lungcan.2018.11.041. 2019
Pain Standards for Accredited Healthcare Organizations (ACDON Project): A Mixed Methods Study.
Perez, Concepcion; (...); Mira, Jose J.
Article. 10.3390/jpm11020102. 2021
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
Garcia-Robles, Ana; (...); Carrascosa, MA
Article. 10.3389/fped.2020.00372. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory
Gaya, Anna; (...); Vallejo, Carlos
Meeting Abstract. 10.1182/blood-2023-185939. 2023
Parasitic Infections in Hematopoietic Stem Cell Transplantation.
Article. 10.4084/MJHID.2016.035. 2016
Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.
Sanz J; (...); Piñana JL
Article. 10.1016/j.bbmt.2019.08.020. 2020
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martin Garcia-Sancho, Alejandro; (...); Cordoba, Raul
Article. 10.1111/bjh.18941. 2023
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
PHARMACOECONOMIC ANALYSIS OF THE USE OF VORICONAZOLE, POSACONAZOLE AND MICAFUNGIN IN THE PRIMARY PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS IN SPAIN
Grau S; (...); Rubio-Terrés C
Meeting Abstract. 10.1016/j.jval.2015.09.1944. 2015
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.2174/1389200218666171101124931. 2018
Pharmacogenomics and the treatment of acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Review. 10.2217/pgs-2016-0055. 2016
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.
Calleja Hernández MÁ; (...); Aragon, B
Article. 10.7399/fh.2017.41.1.10463. 2017
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Robak, T; (...); Jolles, S
Article. 10.1182/bloodadvances.2020002003. 2020
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study
Morillo, ED; (...); Spanish Head Neck Canc Cooperative
Article. 10.1016/j.oraloncology.2016.09.009. 2016
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Cabrero, M; (...); Caballero, D
Article. 10.1016/j.bbmt.2016.10.003. 2017
Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2017
Pilot evaluation of home delivery programme in haemophilia
Megias-Vericat, JE; (...); Poveda-Andres, JL
Article. 10.1111/jcpt.12718. 2018
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis
Megías-Vericat JE; (...); Aliño SF
Letter. 10.1038/tpj.2015.79. 2016
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Article. 10.1080/10428194.2018.1474462. 2019
Practical guide to emergency treatment of thrombotic microangiopathy
Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La
Editorial Material. 10.1016/j.medcli.2018.01.013. 2018
Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process
Valero, S; (...); Poveda, JL
Article. 10.1016/j.yrtph.2018.03.001. 2018
Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-125580. 2019
PREDICTORS OF TREATMENT FREE RESPONSES WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH PTI
Lozano Almela, M. L.; (...); Vicente, V.
Meeting Abstract. 2019
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
Preliminarily results of the Oncohabitats Study: A multicentre validation of overall survival (OS) estimation of patients with glioblastoma (GBM) using vascular biomarkers
Alvarez-Torres, MD; (...); Garcia-Gomez, JM
Meeting Abstract. 10.1158/1538-7445.AM2019-4258. 2019
Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.
García-Robles A; (...); Aguar-Carrascosa M
Letter. 10.1016/j.anpedi.2020.06.008. 2021
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry
Villegas, A; (...); Urbano, A
Article. 10.1007/s00277-017-3059-x. 2017
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
Vidal, OJJ; (...); Palanca, S
Meeting Abstract. 2019
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.
Gonzalez-Lopez, Tomas Jose; (...); Fernandez-Fuertes, Fernando
Article. 10.1016/j.blre.2023.101112. 2023
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group
Franco Pérez F; (...); Provencio M
Article. 10.1016/j.clml.2016.09.004. 2017
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC)
Juan, O; (...); Codina, JG
Meeting Abstract. 10.1016/S1556-0864(18)30411-8. 2018
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC) patients treated with ablative therapy.
Antonio Mendez, Juan; (...); Juan Vidal, Oscar
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e21089. 2018
Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer.
Bruixola, G; (...); Cervantes, A
Article. 10.1136/esmoopen-2018-000425. 2018
Prognostic Value of Event-Free Survival at 12 and 24 Months and Long-Term Mortality for Non-Hodgkin Follicular Lymphoma Patients: A Study Report From the Spanish Lymphoma Oncology Group
Provencio, M; (...); Spanish Lymphoma Oncology Grp
Article. 10.1002/cncr.30795. 2017
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Tamariz-Amador, Luis-Esteban; (...); Troconiz, Inaki F.
Article. 10.1016/j.clml.2022.04.024. 2022
Progression-free survival at 2years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma
Jimenez-Ubieto, A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative stu
Article. 10.1002/cam4.1217. 2017
Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
Pedrosa, Lucia; (...); Sanchez-Beato, Margarita
Article. 10.1038/s41598-020-80376-0. 2021
Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1097/DSS.0000000000001046. 2017
Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker
Perez-Alenda, S; (...); Querol, F
Letter. 10.1111/hae.13388. 2018
Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.
Gonzalez-Lopez, Tomas Jose; (...); Jarque, Isidro
Article. 10.1080/09537104.2024.2336104. 2024
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta, Pau; (...); Villanueva, Miguel
Article. 10.1016/j.clml.2021.07.022. 2021
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).
Mingot-Castellano, Maria Eva; (...); Pascual-Izquierdo, Cristina
Article. 10.3390/jcm12206422. 2023
Recommendations of GeSIDA/PETHEMA on the Diagnosis and Treatment of Lymphomas in Patients Infected by the Human Immunodeficiency Virus
Miralles, P; (...); Santasusana, JMR
Editorial Material. 10.1016/j.medcli.2017.11.037. 2018
Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-167247. 2022
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Lakhwani S; (...); Hernández MT
Article. 10.3324/haematol.2023.284154. 2024
Reduction in alert fatigue in an assisted electronic prescribing system, through the Lean Six Sigma methodology.
Cuéllar Monreal MJ; (...); Poveda Andrés JL
Article. 10.7399/fh.2017.41.1.10434. 2017
Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos.
García-Vidal C, Vázquez L, Jarque I
Article. 10.1016/j.riam.2021.03.001. 2021
Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients
de Latour, RP; (...); Risitano, A
Meeting Abstract. 2020
RESULTS OF THE PEGASUS PHASE III TRIAL FOR THE COMPARISON OF PEGCETACOPLAN WITH ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Jarque, Isidro; (...); Peffault, de latour Regis
Meeting Abstract. 2020
RETROSPECTIVE CONTROL CASE STUDY ON THE EFFICACY OF AUTOLOGOUS TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS IN THE FIRST LINE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA
Parra, ML; (...); Martin, A. A.
Meeting Abstract. 2017
Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partioning analysis (RPA) model modification
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
Robak, Tadeusz; (...); Jolles, Stephen
Meeting Abstract. 10.1182/blood-2019-129839. 2019
Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastastic head and neck squamous cell (PR R/M HNSCC) patients (pts): Real-life experience
Bruixola, G; (...); Borgonon, MP
Meeting Abstract. 2018
Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.
Article. 10.1111/ajt.14580. 2018
Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry
Jimenez-Ubieto, A; (...); Lahuerta, JJ
Letter. 10.1038/s41409-018-0096-6. 2018
Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option
Roman, E; (...); Gorriz, JL
Review. 10.1016/j.nefro.2017.01.006. 2017
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
SEOM clinical guideline in nasopharynx cancer (2017)
Pastor, M; (...); Mesia, R
Article. 10.1007/s12094-017-1777-0. 2018
SEOM clinical guidelines for the treatment of head and neck cancer (2017)
Docampo, LCI; (...); Hernandez, JJC
Article. 10.1007/s12094-017-1776-1. 2018
SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022).
Guma, Josep; (...); Provencio, Mariano
Article. 10.1007/s12094-023-03206-5. 2023
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Aguas Peris M; (...); Nos, P
Article. 10.1097/MIB.0000000000001182. 2017
Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
Meeting Abstract. 2017
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
Villegas A; (...); Urbano-Ispizua Á
Editorial Material. 10.1016/j.medcli.2015.12.012. 2016
Standardized mortality ratios and event-free survival as new prediction tools of early increase in mortality in follicular lymphoma
Franco, F; (...); Pulla, MP
Meeting Abstract. 2017
Survival in young adults diagnosed with follicular lymphoma
Calvo, V; (...); Rueda, A
Letter. 10.1093/annonc/mdv627. 2016
Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease
Lakhwani, Sunil; (...); Teodoro Hernandez Garcia, Miguel
Meeting Abstract. 10.1182/blood-2023-179452. 2023
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients
Simarro, Javier; (...); Palanca, Sarai
Article. 10.3390/ijms23158526. 2022
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
THE LASTING RESPONSE OF ELTROMBOPAG IN PRIMARY PTI IS A PREDICTOR FOR THE PROBABILITY OF DISCONTINUING THE SUCCESS OF ELTROMBOPAG
Porras, JRG; (...); Bastida, J. M.
Meeting Abstract. 2017
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus
Torrent-Farnell, J; (...); Lizan, L
Article. 10.1016/j.healthpol.2018.03.002. 2018
THROMBOTIC EVENTS IN PATIENTS WITH PTI TREATED WITH THROMBOPOIETIN RECEPTOR AGONISTS. IDENTIFICATION OF PREDISPOSING FACTORS
Lozano Almela, M. L.; (...); Vicente, V.
Meeting Abstract. 2019
Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.
Marques MR; (...); Mangas-Sanjuan V
Article. 10.1111/apa.14944. 2020
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group
Mendez, M; (...); Provencio, M
Article. 10.1002/hon.2601. 2019
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma
Cejalvo, MJ; (...); de la Rubia, J
Article. 10.1007/s00277-021-04529-5. 2021
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
Gonzalez-Rincon, J; (...); Sanchez-Beato, M
Article. 10.1371/journal.pone.0212813. 2019
Update of the Grupo Espanol de Leucemia Linfocitica Cronica clinical guidelines of the management of chronic lymphocytic leukemia
Garcia-Marco, JA; (...); Bosch, F
Editorial Material. 10.1016/j.medcli.2016.12.030. 2017
Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy
Garcia, SV; (...); Andres, JLP
Article. 10.1016/j.yrtph.2018.10.002. 2018
Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients
García-Robles AA; (...); Poveda JL
Letter. 10.1016/j.jns.2016.04.048. 2016
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
González-López TJ; (...); García-Frade LJ
Article. 10.1111/ejh.13370. 2020
Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients
Rodriguez-Veiga, Rebeca; (...); Sanz, Miguel A.
Article. 10.1111/myc.12891. 2019
Validation of a risk score for post-engraftment invasive fungal disease in 414 adult allogeneic hematopoietic stem cell transplant recipients
Montesinos, P.; (...); Sanz, M. A.
Meeting Abstract. 2016
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023
VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study
Dachs, LR; (...); Blade, J
Meeting Abstract. 10.1182/blood-2018-99-111924. 2018